NDA 204042 · Janssen Pharms
Invokana
Canagliflozin · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jun 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Mar 29, 2013
Approved uses
8
Original approval plus efficacy supplements
Registered trials
156
25 Phase 3, 13 recruiting
FAERS reports
29,868
19,370 serious, 700 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 21, 2026.
INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). To reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). Not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m 2 ( 1 ). Limitations of Use INVOKANA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . INVOKANA is not recommended for use to improve glycemic control in patients with type 2 diabetes...
Mechanism: SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RT G ), and thereby increases urinary glucose excretion (UGE). Canagliflozin increases the delivery of sodium to the distal tubule by blocking SGLT2-dependent glucose and sodium reabsorption. This is believed to increase tubuloglomerular feedback and reduce intraglomerular pressure.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2024 Supplement 43 · Efficacy · priority review LabelMedication GuideLetter
- Aug 18, 2020 Supplement 34 · Efficacy LetterLabel
- Sep 27, 2019 Supplement 32 · Efficacy · priority review LetterLabelReview
- Oct 29, 2018 Supplement 27 · Efficacy LabelLetterReview
- Feb 1, 2017 Supplement 18 · Efficacy LetterLabel
- May 20, 2016 Supplement 15 · Efficacy LabelLetter
- Sep 10, 2015 Supplement 6 · Efficacy Label
- Mar 29, 2013 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
2 products under this application
- INVOKANA · CANAGLIFLOZIN 300MG · TABLET, ORAL · Prescription · TE AB
- INVOKANA · CANAGLIFLOZIN 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Canagliflozin" as an intervention, any sponsor and status, largest first.
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01989754 · 5,813 participants · Start Jan 16, 2014 · Primary completion Feb 23, 2017
Drug: Placebo; Canagliflozin, 100 mg and 1 more · For: Diabetes Mellitus, Type 2; Albuminuria
Sites: Little Rock, Arkansas; Carmichael, California; Concord, California · 341 sites in all
- Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02065791 · 4,401 participants · Start Feb 17, 2014 · Primary completion Oct 30, 2018
Drug: Canagliflozin; Placebo · For: Diabetes Mellitus, Type 2; Diabetic Nephropathy
Sites: Birmingham, Alabama; Montgomery, Alabama; Tempe, Arizona · 575 sites in all
- CANVAS - CANagliflozin cardioVascular Assessment StudyPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01032629 · 4,330 participants · Start Dec 9, 2009 · Primary completion Feb 22, 2017
Drug: Placebo; Canagliflozin (JNJ-28431754) 100 mg and 1 more · For: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Sites: Birmingham, Alabama; Mesa, Arizona; Tucson, Arizona · 305 sites in all
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTEPivotal-lookingCompleted
Matthew Neal MDAcademic, hospital or other
NCT04505774 · 3,591 participants · Start Sep 4, 2020 · Primary completion Aug 31, 2023
Drug: theraputic heparin; prophylactic heparin and 3 more · For: Covid19
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 101 sites in all
- CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepiridePivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT00968812 · 1,452 participants · Start Sep 2009 · Primary completion Dec 2011
Drug: Glimepiride; Canagliflozin (JNJ-28431754) and 1 more · For: Diabetes Mellitus, Type 2
Sites: Calera, Alabama; Gilbert, Arizona; Mesa, Arizona · 138 sites in all
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT01387737 · 1,299 participants · Start May 2011 · Primary completion Nov 2012
Drug: TA-7284-Low; TA-7284-High · For: Type 2 Diabetes Mellitus
Sites: Chugoku, Japan; Hokkaido, Japan; Kanto, Japan · 7 sites in all
- The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)Pivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01106677 · 1,284 participants · Start May 2010 · Primary completion Oct 2011
Drug: Placebo; Canagliflozin and 2 more · For: Diabetes Mellitus, Type 2
Sites: Little Rock, Arkansas; Fountain Valley, California; National City, California · 125 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diabetic ketoacidosis3,441
- toe amputation2,196
- osteomyelitis2,165
- acute kidney injury2,008
- fungal infection1,447
- weight decreased1,349
- blood glucose increased1,235
- gangrene1,086
- cellulitis1,036
- nausea1,026
- off label use1,021
- urinary tract infection1,019
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 246 |
| 2014 | 984 |
| 2015 | 7,889 |
| 2016 | 4,292 |
| 2017 | 4,362 |
| 2018 | 4,643 |
| 2019 | 2,386 |
| 2020 | 1,465 |
| 2021 | 824 |
| 2022 | 811 |
| 2023 | 690 |
| 2024 | 502 |
| 2025 | 477 |
| 2026 | 291 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Invokana (Canagliflozin)
2024 spending
$272M
Beneficiaries
55,993
255,843 claims
Per beneficiary
$4,859
$18.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $571,448,119 |
| 2021 | $456,386,878 |
| 2022 | $427,366,295 |
| 2023 | $357,419,494 |
| 2024 | $272,062,235 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal B, Perkovic V, Mahaffey KW, et al. · N Engl J Med 2017 · Multicenter Study, Randomized Controlled Trial
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A, Avgerinos I, Karagiannis T, et al. · Ann Intern Med 2020 · Comparative Study, Research Support, Non-U.S. Gov't
- Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Lazzaroni E, Ben Nasr M, Loretelli C, et al. · Pharmacol Res 2021 · Systematic Review
- Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T, Hadnorntun P, Leelahavarong P, et al. · Front Endocrinol (Lausanne) 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R, Uthman O, Cummins E, et al. · Health Technol Assess 2017 · Systematic Review, Network Meta-Analysis
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.